CTOR Dhuwit awis perusahaan citiusonc.com

Tandha merek Citius Oncology (CTOR)

What are the growth horizons for Citius Oncology, Inc. (CTOR) amid strict FDA control over therapy costs? The high authority of the developer of targeted drugs for leukemia confirms the potential, while changes in cash holdings demonstrate the actual volume of reserves. Meanwhile, the level of 0.02 reflects the current magnitude of liquidity. Ultimately, the integration of Lymphir into lymphoma treatment protocols solidifies the company's status as a key player in the orphan drug niche.

Cadangan dhuwit perusahaan: Citius Oncology, Inc (CTOR) kanggo 14.08.2024 - 21.11.2026

Rincian metrik lan analitis perusahaan Citius Oncology Inc. (CTOR)

- nilai saham lan prakiraan konsensus rega:
Analisis kabeh metrik perusahaan:CTOR Citius Oncology, Inc.
Produk merek Citius Oncology

This indicator reflects the current liquidity of the issuer, serving as a measure of its ability to fund operating activities without external borrowing. By analyzing the size of cash resources, an investor assesses the burn rate and the company's independence from credit markets. The metric aggregates all cash and equivalents, determining the financial stability of the business. For Citius Oncology, Inc. (CTOR), this is critical, as the commercialization of the drug requires expenditures in the absence of major manufacturing assets.

Perusahaan pesaing

Volume dana dhuwit perusahaan ONC|HALO - Cadangan dhuwit perusahaan|Revolution Medicines - Dhuwit awis perusahaan|Volume dana dhuwit perusahaan Ascentage Pharma AAPG|CGON - Dana dhuwit perusahaan|Total volume dana dhuwit perusahaan URGN|BCAX: Volume dana dhuwit perusahaan|PSNL - Aset likuid perusahaan|ERAS (Erasca Inc) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Delcath Systems Inc DCTH|Dana dhuwit perusahaan YmAbs (YMAB)|Aset likuid perusahaan Aura Bio|Volume dana dhuwit perusahaan CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Cadangan dhuwit perusahaan|SELLAS Life Sciences Group - Volume dana dhuwit perusahaan|ACTU - Volume dana dhuwit perusahaan|HURA: Volume dana dhuwit perusahaan|Total volume dana dhuwit perusahaan TARA (Protara)|FATE (fatetherapeutics.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Aadi Bioscience WHWK|Volume dana dhuwit perusahaan TCRX|CSBR - Cadangan dhuwit perusahaan|XBiotech - Dhuwit awis perusahaan|CEL-SCI Corporation (CVM) - Cadangan dhuwit perusahaan|OSTX - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Radiopharm Theranostics Ltd|ARTV (artivabio.com) - Dhuwit awis perusahaan|ANL (Adlai Nortye Ltd) - Dana dhuwit perusahaan|Dhuwit awis perusahaan VERU|Tempest Therapeutics (TPST) - Aset likuid perusahaan|Volume dana dhuwit perusahaan XLO|Dhuwit awis perusahaan Renovaro RENB|Volume dana dhuwit perusahaan MURA (Mural Oncology PLC)|KAPA - Dhuwit awis perusahaan|OnKure Therapeutics - Volume dana dhuwit perusahaan|w2.cytomed.sg - Gunggung dana dhuwit perusahaan|Curis Corp (CRIS) - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Apollomics Corp (APLM)|Dana dhuwit perusahaan Tharimmune|Volume dana dhuwit perusahaan advanbiomed.com|Dana dhuwit perusahaan Genprex, Inc (GNPX)|Aset likuid perusahaan Calidi Biotherapeutics, Inc.|Volume dana dhuwit perusahaan SBFM (Sunshine Biopharma Inc.)|XBIO - Dhuwit awis perusahaan|SLRX: Dhuwit awis perusahaan|Sisa dhuwit perusahaan PPBT (Purple Biotech Ltd.)|AONC: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan BeOne Medicines (BGNE)|Dana dhuwit perusahaan Checkpoint Therapeutics, Inc.|Dhuwit awis perusahaan Elevation Oncology (ELEV)|Dana dhuwit perusahaan iCAD Corp (ICAD)|Dhuwit awis perusahaan Ikena IKNA|Volume dana dhuwit perusahaan NTBL (notablelabs.com)|VIRX - Dhuwit awis perusahaan|MOR: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan